July 30, 2014 5:37 AM ET

Biotechnology

Company Overview of F2G Ltd

Company Overview

F2G Ltd. operates as a biotechnology company that engages in the discovery and development of drugs to treat life threatening systemic fungal diseases in at-risk patient populations. It primarily focuses on developing an F3 series of anti mould compounds, which is an antifungal agent that acts through a mechanism different from various marketed drugs. F2G Ltd. was founded in 1998 and is based in Manchester, the United Kingdom.

Lankro Way

Eccles

Manchester,  M30 0LX

United Kingdom

Founded in 1998

Phone:

44 1617 851 270

Fax:

44 1617 851 273

Key Executives for F2G Ltd

Chief Executive Officer and Executive Director
Age: 53
Chief Operating Officer
Chief Scientific and Development Officer
Non-Executive Chairman and Member of Management Board
Age: 71
Compensation as of Fiscal Year 2014.

F2G Ltd Key Developments

F2G Ltd. and University of Manchester Announce a New €6.1 Million Project to Develop New Antifungal Agents

F2G Ltd. and University of Manchester announced the commencement of a EUR 6.1 million EU-funded project to discover and develop novel antifungal drugs to treat serious, life-threatening fungal infections. The NOFUN project is a collaborative project under the 7th Framework Program of the European Commission which brings together five partners to accelerate the development of a number of F2G’s broad spectrum antifungal agents. About two million people die each year because of fungal infection and resistance is rapidly emerging to the most common drugs used to treat these diseases. This project aims to develop novel agents with completely new ways of acting in order to combat the increasing tide of drug resistant fungal infections. NOFUN will use F2G’s discovery assets and the University’s fungal genomics platforms in addition to the drug development and characterisation expertise of the other partners.

F2G Ltd. Appoints Ian Nicholson as Director and Chief Executive Officer

F2G Ltd. announced the appointment of Ian Nicholson to the position of CEO and to the Board of Directors. Ian is currently, and will remain, an Operating Partner of London-based Advent Life Sciences LLP.

F2G Ltd. Appoints John H. Rex to Board of Directors

F2G Ltd. announced the appointment of Dr. John H. Rex to the company’s Board as an Independent Director. He has a BA in Biochemistry from Rice University, an MD from Baylor College of Medicine, and is Vice President and Head of Infection, Global Medicines Development, at AstraZeneca. Dr. Rex, who will continue his role at AstraZeneca.

Similar Private Companies By Industry

Company Name Region
Plasticell Ltd. Europe
Immune Regulation Limited Europe
Intercytex Limited Europe
NeuroTargets Ltd. Europe
Porton International Plc Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact F2G Ltd, please visit www.f2g.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.